GALT — GALECTIN THERAPEUTICS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1133416 ·
Last close
$4.06
Market Cap
$267.38M
52W High
$5.19
52W Low
$2.03
ADV30
850,293
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -4,077,000 | -5,046,000 | 15,759,000 | 14,111,000 | 145,996,000 |
| Dec 2025 | 0 | — | -3,365,000 | -5,500,000 | 19,532,000 | 17,720,000 | 145,727,000 |
| Sep 2025 | 0 | — | -4,198,000 | -8,184,000 | 12,865,000 | 11,525,000 | 138,168,000 |
| Jun 2025 | 0 | — | -4,625,000 | -7,521,000 | 15,602,000 | 13,771,000 | 132,769,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-20,052,000
Investing CF
—
Financing CF
$26,732,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.48
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-437,613,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-18,678,000
Pretax Income TTM
$-26,251,000
Interest Exp TTM
$7,573,000
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -20,085,000 | -30,836,000 | 19,532,000 | 145,727,000 | — | -23,875,000 |
| Dec 2024 | 0 | -42,433,000 | -47,047,000 | 17,495,000 | 120,565,000 | — | -41,767,000 |
| Dec 2023 | 0 | -38,072,000 | -41,066,000 | 28,200,000 | 88,441,000 | — | -32,965,000 |
| Dec 2022 | 0 | -38,352,000 | -38,776,000 | 21,285,000 | 53,479,000 | — | -31,056,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.68
Max Pain — expiry 2026-07-17
max pain strike: $2.50 · spot: $4.06 · call oi: 11,604 · put oi: 291
Expected Move to 2026-07-17:
±$1.20
(29.56%) —
implied range
$2.86 –
$5.26
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TRDA | Entrada Therapeutics, Inc. | $268.64M | $6.92 | — |
| ADAG | Adagene Inc. | $260.33M | $3.94 | — |
| MGNX | MACROGENICS INC | $275.23M | $4.33 | — |
| PRE | Prenetics Global Ltd | $275.39M | $17.86 | — |
| SIGA | SIGA TECHNOLOGIES INC | $257.49M | $3.59 | — |
News headlines (Yahoo Finance, 1h cache)
GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH
2026-06-24 14:05 · Yahoo
GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial
2026-06-23 17:47 · Yahoo
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
2026-06-23 12:00 · Yahoo
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis
2026-05-27 12:00 · Yahoo
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
2026-05-15 12:00 · Yahoo
Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology
2026-05-11 12:00 · Yahoo
Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?
2026-04-03 16:00 · Yahoo
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update
2026-03-31 12:00 · Yahoo
Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.
2026-03-17 12:00 · Yahoo
Galectin Therapeutics Highlights Belapectin Data in MASH Cirrhosis KOL Event, Eyes Next Steps
2026-03-17 02:34 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.